
    
      This is an open label extension study in subjects who are 6 years of age or older with Sickle
      Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002). This study
      is designed to evaluate the safety and describe the efficacy of rivipansel as treatment for
      one or more vaso-occlusive crisis (VOC) events in hospitalized subjects with SCD.
    
  